C2i Genomics

C2i Genomics helps doctors and patients fight cancer by providing doctors and patients with tumor burden information, starting with only a blood sample.  Its service, called C2, uses software that performs pattern recognition on data from whole-genome sequencing of the blood sample.  Physicians can use the service to monitor their patient’s response to treatment and detect treatment failure or disease recurrence well before they would do otherwise.  Physicians can also use the service to measure treatment response in clinical trials.

Volastra Therapeutics, Inc.

Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers.  The company focuses on developing therapies for metastatic cancers by targeting key pathways related to chromosomal instability, a hallmark of cancer metastasis. The majority of oncology therapeutics target alterations widely found in primary tumors while metastasis is responsible for approximately 90% of cancer deaths. Volastra hopes to change the treatment paradigm for patients by developing novel therapeutics specifically tailored to advanced disease.

Swiftscale Biologics, Inc.

Swiftscale Biologics provides fast production services for biologics. At any scale from micrograms to grams, Swiftscale can produce proteins. Swiftscale can produce antibodies, enzymes, receptors, and other complex protein forms. Swiftscale was co-founded by Matthew DeLisa, a professor at Cornell, and Michael Jewett, a professor at Northwestern. In 2019, Swiftscale Biologics had a post valuation of $12.50M.

 

 

Akelos, Inc.

Akelos Inc. is a biopharmaceutical clinical company developing novel non-opioid, anti-hyperalgesic drugs for the treatment of neuropathic pain. Their compounds are intended to selectively and potently inhibit HCN1 channel activity to limit pain.

Big Blue Biotech

Big Blue Biotech produces a novel catheter system designed to decrease the risk of contamination of urine specimens with peri-urethral bacteria when obtaining urine specimens from pediatric patients via bladder catheter.

Halomine Inc. DBA AvantGuard

Halomine Inc. DBA AvantGuard is creating innovative solutions that manage surfaces and provide long-term protection against viruses, bacteria, and fungi/mold in a variety of applications. The company’s proprietary combinations of specialty molecules and polymers are customized to provide prolonged antimicrobial efficacy to a wide range of surfaces and materials.

Exostellar, Inc.

Exostellar, Inc. (formerly Exotanium) is a cloud resource optimization and management platform that uses Artificial Intelligence (AI) and Machine Learning (ML) to help enterprises reduce spending in the cloud by up to 90% while enhancing both operational security and performance.

Organic Robotics Corporation

Organic Robotics Corporation is building smart fabrics to deliver accurate motion capture and fast pressure sensing. The company has worked with accelerators/incubators Luminate NY Accelerator, RevIthaca StartupWorks, and Capital Factory.

Sonder Medicine Inc.

Sonder Medicine uses extracellular vesicles from the vitreous humor as a potent vector to efficiently deliver recombinant proteins into the sensory tissue of the eye, the retina. Their proprietary technology can transport various payloads, including therapeutic proteins, nucleic acids and antibodies into the tissues of the human eye.

 

Aufbau Medical Innovations Ltd., wholly owns Sonder Medicine Inc., doing business as Sonder Research X in the United States.

 

bloXroute Labs, Inc.

bloXroute is a blockchain scalability solution that allows all cryptocurrencies and blockchains to scale to thousands of transactions per second (TPS) on-chain, without any protocol changes. bloXroute solves the scalability bottleneck by addressing the substantial time required for all nodes to synchronize when handling large volumes of TPS. Most importantly, bloXroute does this in a provably neutral way.